Literature DB >> 2543778

Identification and preliminary use of recombinant lambda gt11 fusion proteins in human cytomegalovirus diagnosis.

A Ripalti1, M P Landini, E S Mocarski, M La Placa.   

Abstract

We have isolated reactive clones from a lambda gt11 expression library of human cytomegalovirus (HCMV) DNA using HCMV-positive human sera. Among the recombinant clones obtained, one carried a fragment encoding a portion of p52, the major non-structural DNA-binding protein of 52K (p52) and another carried a part of the gene coding for pl50, the major structural phosphoprotein. These two fusion proteins were examined by immunoblot analysis to test their ability to bind specific antibodies in human sera. The results showed that high titres of antibody to the DNA-binding protein are present in sera of patients undergoing acute HCMV infection, whereas high titres of antibodies to the structural phosphoprotein are widespread in the healthy HCMV-seropositive population. The use of these fusion proteins as antigens for differential screening of serum as a way of detecting recent HCMV infection is discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2543778     DOI: 10.1099/0022-1317-70-5-1247

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  12 in total

1.  Comparison of immunoblotting with other serological methods and virus isolation for the early detection of primary cytomegalovirus infection in allograft recipients.

Authors:  H Miller; B McCulloch; M P Landini; E Rossier
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

2.  Large-scale screening of human sera with cytomegalovirus recombinant antigens.

Authors:  M P Landini; M X Guan; G Jahn; W Lindenmaier; M Mach; A Ripalti; A Necker; T Lazzarotto; B Plachter
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

3.  Human cytomegalovirus structural proteins: immune reaction against pp150 synthetic peptides.

Authors:  M P Landini; A Ripalti; K Sra; P Pouletty
Journal:  J Clin Microbiol       Date:  1991-09       Impact factor: 5.948

4.  Cytomegalovirus-specific antibodies to an immediate early antigen and a late membrane antigen and their possible role in controlling secondary cytomegalovirus infection.

Authors:  J van Zanten; M van der Giessen; L H van der Voort; W J van Son; W van der Bij; T H The
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

5.  Antibody response to recombinant lambda gt11 fusion proteins in cytomegalovirus infection.

Authors:  M P Landini; T Lazzarotto; A Ripalti; M X Guan; M La Placa
Journal:  J Clin Microbiol       Date:  1989-10       Impact factor: 5.948

6.  Humoral immune response to human cytomegalovirus DNA polymerase.

Authors:  M P Landini; T Lazzarotto; P F Ertl
Journal:  J Clin Microbiol       Date:  1993-03       Impact factor: 5.948

Review 7.  Humoral immune response to human cytomegalovirus infection: diagnostic potential of immunoglobulin class and IgG subclass antibody response to human cytomegalovirus early and late antigens.

Authors:  B Weber; W Braun; J Cinatl; H W Doerr
Journal:  Clin Investig       Date:  1993-04

8.  Recombinant mono- and polyantigens to detect cytomegalovirus-specific immunoglobulin M in human sera by enzyme immunoassay.

Authors:  M P Landini; T Lazzarotto; G T Maine; A Ripalti; R Flanders
Journal:  J Clin Microbiol       Date:  1995-10       Impact factor: 5.948

9.  Construction of polyepitope fusion antigens of human cytomegalovirus ppUL32: reactivity with human antibodies.

Authors:  A Ripalti; Q Ruan; M C Boccuni; F Campanini; G Bergamini; M P Landini
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

10.  Lack of correlation between virus detection and serologic tests for diagnosis of active cytomegalovirus infection in patients with AIDS.

Authors:  T Lazzarotto; P Dal Monte; M C Boccuni; A Ripalti; M P Landini
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.